×
PolyPid EBITDA 2019-2025 | PYPD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
PolyPid ebitda from 2019 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
PolyPid EBITDA 2019-2025 | PYPD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
PolyPid ebitda from 2019 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$72.3B
Zoetis (ZTS)
$69B
Daiichi Sankyo, - (DSNKY)
$51.1B
Takeda Pharmaceutical (TAK)
$48.4B
BeOne Medicines - (ONC)
$34.3B
Sandoz Group AG (SDZNY)
$26.7B
Summit Therapeutics (SMMT)
$18.8B
Merck (MKKGY)
$16.7B
Shionogi (SGIOY)
$15.1B
United Therapeutics (UTHR)
$14.1B
Neurocrine Biosciences (NBIX)
$13.2B
Orion OYJ (ORINY)
$11.2B
IPSEN (IPSEY)
$11.2B
Eisai (ESAIY)
$9.4B
Madrigal Pharmaceuticals (MDGL)
$8.4B
Corcept Therapeutics (CORT)
$7.4B
Grifols, S.A (GRFS)
$7B
Stevanato Group S.p.A (STVN)
$6.8B
Ionis Pharmaceuticals (IONS)
$6.8B
Hikma Pharmaceuticals Plc (HKMPF)
$5.4B
Ono Pharmaceutical (OPHLF)
$5.4B
Soleno Therapeutics (SLNO)
$3.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.9B
Crinetics Pharmaceuticals (CRNX)
$2.8B
NewAmsterdam Pharma (NAMS)
$2.8B
Hypermarcas (HYPMY)
$2.7B
Catalyst Pharmaceuticals (CPRX)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.3B
Ocular Therapeutix (OCUL)
$2.1B
Endo (NDOI)
$1.8B